In 2017, alectinib was approved by the U.S. FDA for the treatment of ALK+ metastatic NSCLC at a recommended dosage of 600 mg twice daily, based on a randomized, multicenter, open-label trial that included 303 patients, ALEX (NCT02075840) [101, 102]. This evidence concerns the gene ALK and non-small cell lung carcinoma.